Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Vs. Tacrolimus and Methotrexate As Graft-Versus-Host Disease Prevention Among Allogeneic Stem Cell Transplant Patients Receiving Myeloablative Conditioning

Key Points

• Graft-versus-host disease prevention was more effective with post-transplant cyclophosphamide.
• A significant reduction in graft-versus-host disease was observed when combining cyclophosphamide, tacrolimus, and mycophenolate.
• Analysis of treatment outcomes focuses on allogeneic stem cell transplant patients receiving myeloablative conditioning.
• These findings may call for new standards in preventing graft-versus-host disease, enhancing patient care.